Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization

View ORCID ProfileDrew Weissman, Mohamad-Gabriel Alameh, Thushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown, Celia C. LaBranche, Robert J Edwards, Laura Sutherland, Sampa Santra, Katayoun Mansouri, Sophie Gobeil, Charlene McDanal, Norbert Pardi, Nick Hengartner, Paulo J.C. Lin, Ying Tam, Pamela A. Shaw, Mark G. Lewis, Carsten Boesler, Uğur Şahin, Priyamvada Acharya, Barton F. Haynes, Bette Korber, David C. Montefiori
doi: https://doi.org/10.1101/2020.07.22.20159905
Drew Weissman
1Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Drew Weissman
  • For correspondence: drew@pennmedicine.upenn.edu david.montefiori@duke.edu
Mohamad-Gabriel Alameh
1Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thushan de Silva
2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
3South Yorkshire Regional Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Collini
2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
3South Yorkshire Regional Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hailey Hornsby
2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca Brown
2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celia C. LaBranche
4Department of Surgery, Duke University School of Medicine, Durham, North Carolina USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J Edwards
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
6Duke University, Department of Medicine, Durham NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Sutherland
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sampa Santra
7Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katayoun Mansouri
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophie Gobeil
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlene McDanal
4Department of Surgery, Duke University School of Medicine, Durham, North Carolina USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norbert Pardi
1Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Hengartner
8T6: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paulo J.C. Lin
9Acuitas Therapeutics, Vancouver, BC, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Tam
9Acuitas Therapeutics, Vancouver, BC, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela A. Shaw
10Department of Biostatistics, Epidemiology and Informatics University of Pennsylvania Perelman School of Medicine, Philadelphia, PA USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark G. Lewis
11Bioqual Inc., Rockville, MD USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carsten Boesler
12BioNTech, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uğur Şahin
12BioNTech, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priyamvada Acharya
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barton F. Haynes
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bette Korber
8T6: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David C. Montefiori
4Department of Surgery, Duke University School of Medicine, Durham, North Carolina USA
5Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: drew@pennmedicine.upenn.edu david.montefiori@duke.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

The SARS-CoV-2 Spike protein acquired a D614G mutation early in the COVID-19 pandemic that appears to confer on the virus greater infectivity and is now the globally dominant form of the virus. Certain of the current vaccines entering phase 3 trials are based on the original D614 form of Spike with the goal of eliciting protective neutralizing antibodies. To determine whether D614G mediates neutralization-escape that could compromise vaccine efficacy, sera from Spike-immunized mice, nonhuman primates and humans were evaluated for neutralization of pseudoviruses bearing either D614 or G614 Spike on their surface. In all cases, the G614 pseudovirus was moderately more susceptible to neutralization. The G614 pseudovirus also was more susceptible to neutralization by monoclonal antibodies against the receptor binding domain and by convalescent sera from people known to be infected with either the D614 or G614 form of the virus. These results indicate that a gain in infectivity provided by D614G came at the cost of making the virus more vulnerable to neutralizing antibodies, and that the mutation is not expected to be an obstacle for current vaccine development.

Competing Interest Statement

In accordance with the University of Pennsylvania policies and procedures and our ethical obligations as researchers, we report that Drew Weissman is named on patents that describe the use of nucleoside-modified mRNA as a platform to deliver therapeutic proteins. Drew Weissman and Norbert Pardi are also named on a patent describing the use of modified mRNA in lipid nanoparticles as a vaccine platform. We have disclosed those interests fully to the University of Pennsylvania, and we have in place an approved plan for managing any potential conflicts arising from licensing of our patents.

Clinical Trial

NCT04380701

Funding Statement

BioNTech is the Sponsor of the clinical trial study that the human samples were obtained from, N.P. was supported by the NIAID -1R01AI146101, U.S, and C.B. work for BioNTech, M.L. was supported by NIAID - R01AI123738). D.W. was supported by grants from the NIAID - AI142596 and AI124429, IPCAVD - U19AI142596, and BioNTech. B.H. was funded by a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) and NIH grant IPCAVD-U19AI142596, P.A. was funded by NIAID R01 - AI145687 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act), D.M. was funded by NIH - HHSN272201800004C, the Gates Foundation - OPP1146996 and a contract from the State of NC funded by the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). B.K. was funded by the Los Alamos National Laboratory directed research (LDRD) project 20200706ER

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The trial was carried out in Germany in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and with approval by an independent ethics committee (Ethik-Kommission of the Landesarztekammer Baden-Wurttemberg, Stuttgart, Germany) and the competent regulatory authority (Paul-Ehrlich Institute, Langen, Germany). All participants provided written informed consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

I will share all primary data generated as part of this grant. It will be deposited at the National Addiction & HIV Data Archive Program (NAHDAP), which is an NIH-funded repository. Collected samples will be stored at the University of Pennsylvania and available after review of the request by the PI.

https://www.icpsr.umich.edu/icpsrweb/NAHDAP/data/index.jsp

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman, Mohamad-Gabriel Alameh, Thushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown, Celia C. LaBranche, Robert J Edwards, Laura Sutherland, Sampa Santra, Katayoun Mansouri, Sophie Gobeil, Charlene McDanal, Norbert Pardi, Nick Hengartner, Paulo J.C. Lin, Ying Tam, Pamela A. Shaw, Mark G. Lewis, Carsten Boesler, Uğur Şahin, Priyamvada Acharya, Barton F. Haynes, Bette Korber, David C. Montefiori
medRxiv 2020.07.22.20159905; doi: https://doi.org/10.1101/2020.07.22.20159905
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
Drew Weissman, Mohamad-Gabriel Alameh, Thushan de Silva, Paul Collini, Hailey Hornsby, Rebecca Brown, Celia C. LaBranche, Robert J Edwards, Laura Sutherland, Sampa Santra, Katayoun Mansouri, Sophie Gobeil, Charlene McDanal, Norbert Pardi, Nick Hengartner, Paulo J.C. Lin, Ying Tam, Pamela A. Shaw, Mark G. Lewis, Carsten Boesler, Uğur Şahin, Priyamvada Acharya, Barton F. Haynes, Bette Korber, David C. Montefiori
medRxiv 2020.07.22.20159905; doi: https://doi.org/10.1101/2020.07.22.20159905

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (416)
  • Anesthesia (91)
  • Cardiovascular Medicine (860)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (250)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
  • Epidemiology (8562)
  • Forensic Medicine (4)
  • Gastroenterology (384)
  • Genetic and Genomic Medicine (1753)
  • Geriatric Medicine (167)
  • Health Economics (373)
  • Health Informatics (1244)
  • Health Policy (621)
  • Health Systems and Quality Improvement (468)
  • Hematology (196)
  • HIV/AIDS (374)
  • Infectious Diseases (except HIV/AIDS) (10303)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (212)
  • Neurology (1678)
  • Nursing (97)
  • Nutrition (251)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (451)
  • Oncology (929)
  • Ophthalmology (263)
  • Orthopedics (102)
  • Otolaryngology (172)
  • Pain Medicine (114)
  • Palliative Medicine (40)
  • Pathology (253)
  • Pediatrics (536)
  • Pharmacology and Therapeutics (253)
  • Primary Care Research (208)
  • Psychiatry and Clinical Psychology (1770)
  • Public and Global Health (3841)
  • Radiology and Imaging (624)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (168)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)